Á lódáil...
Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia
BACKGROUND: Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in western countries. Standard treatments include mono‐ or polychemotherapies, usually combined with monoclonal antibodies such as rituximab or alemtuzumab. However, the impa...
Na minha lista:
| Foilsithe in: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
John Wiley & Sons, Ltd
2012
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6485963/ https://ncbi.nlm.nih.gov/pubmed/23152253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD008079.pub2 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|